Lestaurtinib

From WikiMD's Food, Medicine & Wellness Encyclopedia

Lestaurtinib

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine, and is being developed by Cephalon.

It is an inhibitor of FLT3,[1] JAK2,[2] TrkA, TrkB and TrkC.[3]

Uses[edit | edit source]

It is undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders.

As of 2009, it is in Phase II clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.[4][5]

See also[edit | edit source]

References[edit | edit source]

  1. ↑
  2. ↑
  3. ↑
  4. ↑ "Oncology pipeline Oct 2009" (PDF).
  5. ↑ "Trials of Lestaurinib".

Stub icon

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

‎

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Retrieved from "https://wikimd.com/w/index.php?title=Lestaurtinib&oldid=4970072"

Contributors: Prab R. Tumpati, MD